Healthcare Private Placement and M&A Transactions Review Week Ending September 3, 2023

Rakuten Medical: The company raised $180 million of venture funding from undisclosed investors on September 1, 2023. The company is a developer of precision-targeted cancer therapies designed to treat solid tumors.

Spencer Health Solutions: The company raised $43 million through a combination of Series D-1 and Series D-2 venture funding from undisclosed investors on August 30, 2023, putting the company’s pre-money valuation at $100 million. The company is a developer of an advanced in-home medication dispenser intended to make it easier for people to live healthy and independent lives.

Antabio: The company is in the process of raising EUR 25 million of Series B venture funding from European Innovation Council Fund on August 29, 2023. The company is an operator of a private European biopharmaceutical company intended to develop novel and highly differentiated antibacterial treatments.

CCM Biosciences: The company raised an estimated $25 million of Series A1 and Series A2 venture funding from Chakrabarti Capital Management and other undisclosed investors on August 29, 2023. The company is an operator of a biopharmaceutical business intended to develop drugs for different indications and associated companion diagnostic tests.

Aclipse Therapeutics: The company is in the process of raising $8 million of venture funding on August 29, 2023. The company is a developer of novel differentiated drugs designed to address diseases for patients with life-threatening and severe diseases.

Rebalance Health: The company raised $7.3 million of Series C venture funding from undisclosed investors on August 28, 2023, putting the company’s pre-money valuation at $24 million. The company is an operator of a health and performance lifestyle company intended to optimize health and fitness.

Cell Microsystems: The company raised $6.5 million of venture funding from undisclosed investors on August 28, 2023. The company is a developer of biological tools designed for single-cell research.

Regenerative Medical Solutions: The company raised $5 million of venture funding from undisclosed investors on August 29, 2023. The company is an operator of a biotechnology company intended to provide regenerative medical products to treat diabetes.

Variational AI: The company is in the process of raising Series A venture funding on August 29, 2023. The company is a developer of an artificial intelligence-based drug discovery platform intended to develop novel and selective kinase inhibitors for solid tumor indications.

NuVasive / Globus Medical: The company was acquired by Globus Medical for $3.1 billion on September 1, 2023. NuVasive Inc is a medical technology company focused on developing, manufacturing, and providing procedural solutions for spine surgery.

Acer Therapeutics / Zevra Therapeutics: The company reached a definitive agreement to be acquired by Zevra Therapeutics for $91 million on August 30, 2023. Acer Therapeutics is a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for patients with a critical unmet medical need.

Mindset Pharma / Otsuka Pharmaceutical: The company reached a definitive agreement to be acquired by Otsuka Pharmaceutical for CAD 80 million on August 31, 2023. Mindset Pharma Inc is a drug discovery and development company focused on creating psychedelic medicines to treat neurological and psychiatric disorders.

BianoScience / EUROAPI Active Solutions for Health: The company reached a definitive agreement to be acquired by EUROAPI Active Solutions for Health for an estimated EUR 10 million on August 29, 2023. The company is a developer of DNA and RNA-based drugs.

Apexigen / Pyxis Oncology: The company was acquired by Pyxis Oncology for $10.7 million on August 29, 2023. Apexigen Inc is a clinical-stage biopharmaceutical company focused on antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient’s immune system to combat cancer.

Pardes Biosciences / MediPacific: The company was acquired by MediPacific for an undisclosed amount on August 31, 2023. Pardes Biosciences Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel oral-antiviral therapeutics to improve the lives of patients suffering from life-threatening disease.